Multidrug-resistant tuberculosis

Caminero Luna, 2003 World Health Organization, 2008 WHO, 2009 Nathanson, 2006, Multidrug-resistant tuberculosis management in resource-limited settings, Emerg Infect Dis, 12, 1389, 10.3201/eid1209.051618 Centers for Disease Control, 1991, Nosocomial transmission of multidrug-resistant tuberculosis among HIV-infected persons – Florida and New York, 1988–1991, JAMA, 266, 1483, 10.1001/jama.1991.03470110027006 Frieden, 1993, The emergence of drug-resistant tuberculosis in New York City, N Engl J Med, 328, 521, 10.1056/NEJM199302253280801 Ritacco, 1997, Nosocomial spread of human immunodeficiency virus-related multidrug-resistant tuberculosis in Buenos Aires, J Infect Dis, 176, 637, 10.1086/514084 Rullán, 1996, Nosocomial transmission of multidrug-resistant Mycobacterium tuberculosis in Spain, Emerg Infect Dis, 2, 125, 10.3201/eid0202.960208 World Health Organization, 2010 Gandhi, 2006, Extensively drug resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa, Lancet, 368, 1575, 10.1016/S0140-6736(06)69573-1 Zignol, 2012, Surveillance of anti-tuberculosis drug resistance in the world: an updated analysis, 2007–2010, Bull World Health Organ, 90, 111, 10.2471/BLT.11.092585 Brasil. Ministério da Saúde. II Inquérito Nacional de Resistência aos Fármacos anti-TB, 2007–2008, dados não publicados. David, 1970, Probability distribution of drug-resistant mutants in unselected populations of Mycobacterium tuberculosis, Appl Microbiol, 20, 810, 10.1128/AEM.20.5.810-814.1970 Cox, 2007, Risk of acquired drug resistance during short-course directly observed treatment of tuberculosis in an area with high levels of drug resistance, Clin Infect Dis, 44, 1421, 10.1086/517536 Supply, 2003, Linkage disequilibrium between minisatellite loci supports clonal evolution of Mycobacterium tuberculosis in a high tuberculosis incidence area, Mol Microbiol, 47, 529, 10.1046/j.1365-2958.2003.03315.x Dalcolmo, 2007, Tuberculose multirresistente no Brasil: histórico e medidas de controle, Rev Saude Publica, 41, 34, 10.1590/S0034-89102007000800006 Zhang, 1992, The catalase-peroxidase gene and isoniazid resistance of Mycobacterium tuberculosis, Nature, 358, 591, 10.1038/358591a0 Zhang, 1993, Genetic basis of isoniazid resistance of Mycobacterium tuberculosis, Res Microbiol, 144, 143, 10.1016/0923-2508(93)90029-2 Heym, 1995, Missense mutations in the catalase-peroxidase gene, katG, are associated with isoniazid resistance in Mycobacterium tuberculosis, Mol Microbiol, 15, 235, 10.1111/j.1365-2958.1995.tb02238.x Ahmad, 2004, Contribution of AGC to ACC and other mutations at codon 315 of the katG gene in isoniazid-resistant Mycobacterium tuberculosis isolates from the Middle East, Int J Antimicrob Agents, 23, 473, 10.1016/j.ijantimicag.2003.10.004 Ferrazoli, 1995, Catalase expression, katG, and MIC of isoniazid for Mycobacterium tuberculosis isolates from Sao Paulo, Brazil, J Infect Dis, 171, 237, 10.1093/infdis/171.1.237 Goto, 1995, KatG sequence deletion is not the major cause of isoniazid resistance in Japanese and Yemeni Mycobacterium tuberculosis isolates, Mol Cell Probes, 9, 433, 10.1006/mcpr.1995.0066 Silva, 2003, Mutations in KatG, inhA and ahpC genes of Brazilian isoniazid resistant isolates of Mycobacterium tuberculosis, J Clin Microbiol, 41, 4471, 10.1128/JCM.41.9.4471-4474.2003 Hofling, 2005, Prevalence of katG Ser315 Mycobacterium tuberculosis isolates from Brazil, Int J Tuberc Lung Dis, 9, 87 Jaber, 1996, Presence of katG gene in resistant Mycobacterium tuberculosis, J Clin Pathol, 49, 945, 10.1136/jcp.49.11.945 Banerjee, 1994, InhA, a gene encoding a target for isoniazid and ethionamide in Mycobacterium tuberculosis, Science, 263, 227, 10.1126/science.8284673 Rinder, 1998, Significance of ahpC promoter mutations for the prediction of isoniazid resistance in Mycobacterium tuberculosis, Eur J Clin Microbiol Infect Dis, 17, 508 Telenti, 1997, Genetics of drug resistance in tuberculosis, Clin Chest Med, 18, 55, 10.1016/S0272-5231(05)70355-5 Carvalho, 2003, Low-stringency single-specificprimer PCR as a tool for detection of mutations in the rpoB gene of rifampin-resistant Mycobacterium tuberculosis, J Clin Microbiol, 41, 3384, 10.1128/JCM.41.7.3384-3386.2003 McCammon, 2005, Detection of rpoB mutations associated with rifampin resistance in Mycobacterium tuberculosis using denaturing gradient gel electrophoresis, Antimicrob Agents Chemother, 49, 2200, 10.1128/AAC.49.6.2200-2209.2005 Zhang, 1994, Molecular genetics of drug resistance in Mycobacterium tuberculosis, J Antimicrob Chemother, 34, 313, 10.1093/jac/34.3.313 WHO, 2010 Ogwang, 2009, Comparison of rapid tests for detection of rifampicin-resistant Mycobacterium tuberculosis in Kampala, Uganda, BMC Infect Dis, 9, 139, 10.1186/1471-2334-9-139 Lawn, 2011, Xpert® MTB/RIF assay: development, evaluation and implementation of a new rapid molecular diagnostic for tuberculosis and rifampicin resistance, Future Microbiol, 6, 1067, 10.2217/fmb.11.84 Vassall, 2011, Rapid diagnosis of tuberculosis with the Xpert MTB/RIF assay in high burden countries: a cost-effectiveness analysis, PLoS Med, 8, e1001120, 10.1371/journal.pmed.1001120 Al-Mutairi, 2011, Performance comparison of four methods for detecting multidrug-resistant Mycobacterium tuberculosis strains, Int J Tuberc Lung Dis, 15, 110 Friedrich, 2011, Suitability of Xpert MTB/RIF and genotype MTBDRplus for patient selection for a tuberculosis clinical trial, J Clin Microbiol, 49, 2827, 10.1128/JCM.00138-11 Bodmer, 2012, Diagnosing pulmonary tuberculosis with the Xpert MTB/RIF test, J Vis Exp, 62, e3547 Tukvadze, 2012, Use of a molecular diagnostic test in AFB smear positive tuberculosis suspects greatly reduces time to detection of multidrug resistant tuberculosis, PLoS One, 7, e31563, 10.1371/journal.pone.0031563 Skenders, 2012, Implementation of the INNO-LiPA Rif.TB® line-probe assay in rapid detection of multidrug-resistant tuberculosis in Latvia, Int J Tuberc Lung Dis, 15, 1546, 10.5588/ijtld.11.0067 Pottathil, 2011, Evaluation of rapid techniques for the detection of mycobacteria in sputum with scanty bacilli or clinically evident, smear negative cases of pulmonary and extra-pulmonary tuberculosis, Mem Inst Oswaldo Cruz, 106, 620, 10.1590/S0074-02762011000500016 World Health Organization, 2009 World Health Organization, 2011 Yee, 2003, Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis, Am J Respir Crit Care Med, 167, 1472, 10.1164/rccm.200206-626OC Nathanson, 2004, Adverse events in the treatment of multidrug-resistant tuberculosis: results from the DOTS-Plus initiative, Int J Tuberc Lung Dis, 8, 1382 Mitnick, 2003, Community-based therapy for multidrug-resistant tuberculosis in Lima, Peru N Engl J Med, 348, 119, 10.1056/NEJMoa022928 Munsiff, 2006, Public-private collaboration for multidrug-resistant tuberculosis control in New York City, Int J Tuberc Lung Dis, 10, 639 Shin, 2007, Adverse reactions among patients being treated for MDR-TB in Tomsk, Russia Int J Tuberc Lung Dis, 11, 1314 Resch, 2006, Cost-effectiveness of treating multidrug-resistant tuberculosis, PLoS Med, 3, e241, 10.1371/journal.pmed.0030241 Lienhardt, 2010, New drugs and new regimens for the treatment of tuberculosis: review of the drug development pipeline and implications for national programmes, Curr Opin Pulm Med, 16, 186 Ma, 2010, Global tuberculosis drug development pipeline: the need and the reality, Lancet, 375, 2100, 10.1016/S0140-6736(10)60359-9 Orenstein, 2009, Treatment outcomes among patients with multidrug-resistant tuberculosis: systematic review and meta-analysis, Lancet Infect Dis, 9, 153, 10.1016/S1473-3099(09)70041-6 Chung, 2007, Factors influencing the successful treatment of infectious pulmonary tuberculosis, Int J Tuberc Lung Dis, 11, 59 Dalcolmo, 1999, Estudo de efetividade de esquemas alternativos para o tratamento da tuberculose multirresistente no Brasil, J Pneumol, 25, 70, 10.1590/S0102-35861999000200003 Conde, 2009, III Diretrizes para Tuberculose da Sociedade Brasileira de Pneumologia e Tisiologia, J Bras Pneumol, 35, 1018, 10.1590/S1806-37132009001000011 Conde, 2009, Moxifloxacin versus ethambutol in the initial treatment of tuberculosis: a double-blind, randomised, controlled phase II trial, Lancet, 373, 1183, 10.1016/S0140-6736(09)60333-0 Brasil. Ministério da Saúde. Secretaria de Vigilância em Saúde. Programa Nacional de Controle da Tuberculose (PNCT). Sistema de Informação em Tuberculose Multirresistente (SITBMR). Available at: http://tbmr.ensp.fiocruz.br/tbmr/Relatorios. Migliori, 2007, Clinical and operational value of the extensively drug-resistant tuberculosis definition, Eur Respir J, 30, 623, 10.1183/09031936.00077307 Sotgiu, 2009, Epidemiology and clinical management of XDR-TB: a systematic review by TBNET, Eur Respir J, 33, 871, 10.1183/09031936.00168008 Bonilla, 2008, Management of extensively drug-resistant tuberculosis in Peru: cure is possible, PLoS One, 3, e2957, 10.1371/journal.pone.0002957 Dheda, 2010, Early treatment outcomes and HIV status of patients with extensively drug-resistant tuberculosis in South Africa: a retrospective cohort study, Lancet, 375, 1798, 10.1016/S0140-6736(10)60492-8 Koh, 2009, Daily 300mg dose of linezolid for the treatment of intractable multidrug-resistant and extensively drug-resistant tuberculosis, J Antimicrob Chemother, 64, 388, 10.1093/jac/dkp171 Migliori, 2009, A retrospective TBNET assessment of linezolid safety, tolerability and efficacy in multidrug-resistant tuberculosis, Eur Respir J, 34, 387, 10.1183/09031936.00009509 Schecter, 2010, Linezolid in the treatment of multidrug-resistant tuberculosis, Clin Infect Dis, 50, 49, 10.1086/648675 Alffenaar, 2010, Comparison of the pharmacokinetics of two dosage regimens of linezolid in multidrug-resistant and extensively drug-resistant tuberculosis patients, Clin Pharmacokinet, 49, 559, 10.2165/11532080-000000000-00000 Anger, 2010, Linezolid use for treatment of multidrug-resistant and extensively drug-resistant tuberculosis, New York City, 2000–06, J Antimicrob Chemother, 65, 775, 10.1093/jac/dkq017 Villar, 2011, Linezolid safety, tolerability and efficacy to treat multidrug- and extensively drug-resistant tuberculosis, Eur Respir J, 38, 730, 10.1183/09031936.00195210 Abbate, 2012, Successful alternative treatment of extensively drug-resistant tuberculosis in Argentina with a combination of linezolid, moxifloxacin and thioridazine, J Antimicrob Chemother, 67, 473, 10.1093/jac/dkr500 Singla, 2012, Linezolid: an effective, safe and cheap drug for patients failing multidrug-resistant tuberculosis treatment in India, Eur Respir J, 39, 956, 10.1183/09031936.00076811 Tangg, 2011, Efficacy and safety of linezolid in the treatment of extensively drug-resistant tuberculosis, Jpn J Infect Dis, 64, 509, 10.7883/yoken.64.509 Leite, 1997, Tratamento cirúrgico adjuvante de tuberculose pulmonar multirresistente, J Pneumol, 23, 11 Dewan, 2006, Surgical interventions in multidrug-resistant tuberculosis: retrospective analysis of 74 patients treated at a tertiary level care center, Ind J Thorac Cardiovasc Surg, 22, 15, 10.1007/s12055-006-0500-5 Somocurcio, 2007, Surgery for patients with drug-resistant tuberculosis: report of 121 cases receiving community-based treatment in Lima, Peru Thorax, 62, 416, 10.1136/thx.2005.051961 Wang, 2008, Pulmonary resection in the treatment of multidrug-resistant tuberculosis: a retrospective study of 56 cases, Ann Thorac Surg, 86, 1640, 10.1016/j.athoracsur.2008.07.056 Mitnick, 2008, Comprehensive treatment of extensively drug-resistant tuberculosis, N Engl J Med, 359, 563, 10.1056/NEJMoa0800106 Gegia, 2012, Adjunctive surgery improves treatment outcomes among patients with multidrug-resistant and extensively drug-resistant tuberculosis, Int J Infect Dis, 16, e391, 10.1016/j.ijid.2011.12.018 Shiraishi, 2009, Aggressive surgical treatment of multidrug-resistant tuberculosis, J Thorac Cardiovasc Surg, 138, 1180, 10.1016/j.jtcvs.2009.07.018 Dravniece, 2009, Adjunctive resectional lung surgery for extensively drug-resistant tuberculosis, Eur Respir J, 34, 180, 10.1183/09031936.00047208 World Health Organization (WHO), 2012 Stop TB Partnership Working Group on New TB Drugs. Available at: http://www.newtbdrugs.org. Lienhardt, 2012, New drugs for the treatment of tuberculosis: needs, challenges, promise, and prospects for the future, J Infect Dis, 205, S241, 10.1093/infdis/jis034 Diacon, 2012, Randomized pilot trial of eight weeks of bedaquiline (TMC207) treatment for multidrug-resistant tuberculosis: long-term outcome, tolerability, and effect on emergence of drug resistance, Antimicrob Agents Chemother, 56, 3271, 10.1128/AAC.06126-11 Lounis N, Lounis E, De Paepe B, Van Baelen K, Andries K. A phase II, open-label trial with TMC207 as part of a multi-drug resistant tuberculosis (MDR-TB) treatment regimen in subjects with sputum smear-positive pulmonary infection with MDR-TB. Clinical Microbiology Report. Janssen Research and Development; 8 May 2012. Gler, 2012, Delamanid for multidrug-resistant pulmonary tuberculosis, N Engl J Med, 366, 2151, 10.1056/NEJMoa1112433 Canetti, 1969, Advances in techniques of testing mycobacterial drug sensitivity, and the use of sensitivity tests in tuberculosis control programmes, Bull World Health Organ, 41, 21